Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma

Kudo, Masatoshi

doi:10.21037/hbsn-21-203

Cited by 11 publications

(2 citation statements)

References 22 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent research has looked into the potential of immune checkpoint inhibitors, adoptive cell therapy, and combination therapies for HCC treatment. Moreover, studies have examined the possibility of enhancing the effectiveness of immunotherapy by targeting immune or stromal cells within the TME [21][22][23] .…”

Section: Discussionmentioning

confidence: 99%

PHLDA2 is a prognostic biomarker associated with tumor immunosuppressive microenvironment in hepatocellular carcinoma

Chen,

Tang,

Wang

2023

Preprint

View full text Add to dashboard Cite

PHLDA2 (pleckstrin homology-like domain, family A, member 2), is primarily found in the placenta and is known to regulate cell growth and apoptosis. It has also been linked to certain types of cancer, though its role in hepatocellular carcinoma (HCC) is unclear. To investigate further, we conducted a bioinformatic analysis, examining gene expression, prognostic function, potential pathways, the tumor microenvironment, and drug resistance. The analysis revealed that PHLDA2 expression generally increased in various tumors, including HCC, and was associated with worse survival rates. Additionally, PHLDA2 expression correlated positively with most immunosuppressive cells, such as tumor-associated macrophages and Tregs. Patients with elevated PHLDA2 expression tended to be resistant to anti-tumor medications. Overall, our study suggests that PHLDA2 may function as an oncogene and prognostic marker in HCC and other cancers, possibly contributing to an immunosuppressive microenvironment.

show abstract

Section: Discussionmentioning

confidence: 99%

PHLDA2 is a prognostic biomarker associated with tumor immunosuppressive microenvironment in hepatocellular carcinoma

Chen,

Tang,

Wang

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Because of its high response rate and good tolerability, the combination of atezolizumab plus bevacizumab is the first-line systemic therapy regimen for HCC [6][7][8][9][10]. In cases in which bevacizumab is not indicated, durvalumab plus tremelimumab is the recommended treatment regimen (Fig.…”

Section: Introductionmentioning

confidence: 99%

Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy

Kudo¹

2023

Liver Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Tumor-immune Co-evolution in hepatocellular carcinoma and its implication for immunotherapy resistance

Fang

Yang

Mao

2022

iLIVER

View full text Add to dashboard Cite

Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma

Abstract: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Cited by 11 publications

References 22 publications

PHLDA2 is a prognostic biomarker associated with tumor immunosuppressive microenvironment in hepatocellular carcinoma

PHLDA2 is a prognostic biomarker associated with tumor immunosuppressive microenvironment in hepatocellular carcinoma

Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy

Tumor-immune Co-evolution in hepatocellular carcinoma and its implication for immunotherapy resistance

Contact Info

Product

Resources

About